Wealthsource Partners LLC boosted its holdings in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 23.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,097 shares of the medical equipment provider’s stock after acquiring an additional 210 shares during the period. Wealthsource Partners LLC’s holdings in ABIOMED were worth $493,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of ABMD. NEXT Financial Group Inc purchased a new position in ABIOMED in the third quarter worth about $115,000. Migdal Insurance & Financial Holdings Ltd. raised its holdings in ABIOMED by 160.2% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 320 shares of the medical equipment provider’s stock worth $144,000 after buying an additional 197 shares during the last quarter. TRUE Private Wealth Advisors purchased a new position in ABIOMED in the third quarter worth about $162,000. OLD Mutual Customised Solutions Proprietary Ltd. purchased a new position in ABIOMED in the second quarter worth about $164,000. Finally, Rampart Investment Management Company LLC purchased a new position in ABIOMED in the second quarter worth about $175,000. 87.27% of the stock is owned by institutional investors.
Shares of ABMD stock opened at $330.67 on Friday. ABIOMED, Inc. has a 52 week low of $187.01 and a 52 week high of $459.75. The company has a market capitalization of $14.74 billion, a PE ratio of 134.97, a P/E/G ratio of 2.67 and a beta of 0.28.
ABMD has been the subject of several recent analyst reports. ValuEngine cut shares of ABIOMED from a “buy” rating to a “hold” rating in a report on Tuesday, November 20th. Morgan Stanley raised shares of ABIOMED from an “equal” rating to a “weight” rating and lifted their target price for the stock from $396.00 to $496.00 in a report on Wednesday, November 7th. BidaskClub cut shares of ABIOMED from a “buy” rating to a “hold” rating in a report on Thursday, November 15th. Finally, BTIG Research raised shares of ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 target price for the company in a report on Friday, November 2nd. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $402.78.
In other news, VP Michael G. Howley sold 10,000 shares of ABIOMED stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $432.50, for a total value of $4,325,000.00. Following the completion of the sale, the vice president now directly owns 48,954 shares in the company, valued at $21,172,605. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.50% of the company’s stock.
ABIOMED Company Profile
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Read More: Is a Roth IRA right for you?
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.